DOBOT grants 2.50 million H-share options; chairman’s allotment requires shareholder vote

Bulletin Express
04/02

Shenzhen DOBOT Corp Ltd (DOBOT) has approved the issuance of 2.50 million H-share options to six employee participants under its H Share Option Scheme, according to a filing with the Hong Kong Stock Exchange on 2 April 2026.

The grant covers four directors and two other employees. Directors receive 2.30 million options—92% of the total—including 1.00 million options for Chairman and General Manager Liu Peichao, 0.50 million each for Executive Directors Wang Yong and Jiang Yu, and 0.30 million for Non-executive Director Lang Xulin. The combined director allocation equals 0.58% of DOBOT’s issued H shares.

Key terms • Exercise price: HK$33.34 per H share, matching the 2 April 2026 closing price and exceeding the five-day average of HK$33.20. • Vesting schedule: Four equal tranches of 25% on 3 April in 2027, 2028, 2029 and 2030. • Exercise window: Three years from each vesting date. • Performance hurdles: Vesting is linked to both group revenue growth against FY 2025 and individual performance ratings. Full vesting requires revenue growth of ≥40% in 2026, ≥96% in 2027, ≥174.40% in 2028 and ≥284.16% in 2029, along with an “A” individual rating. • Clawback: Options may be cancelled or shares reclaimed in cases such as financial misstatement, fraud or serious misconduct. • Financial assistance: None provided for option exercise.

Regulatory considerations Because Mr Liu’s allotment exceeds the 0.1% individual limit within a 12-month period, shareholder approval is required at a forthcoming general meeting; Mr Liu, his associates and core connected persons must abstain from voting.

Scheme capacity Following this grant, DOBOT states that up to 31.35 million H shares remain available for future issuance under its various equity incentive schemes.

Purpose The board cites talent retention, performance alignment and value creation as the objectives of the option grant.

The independent non-executive directors have reviewed and approved all director allocations in accordance with Hong Kong Listing Rule 17.04(1).

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10